Nicox and Glaukos Sign Global Licensing Deal for Glaucoma Drug Candidate

Nicox has entered into an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. The collaboration aims to accelerate research and development efforts for glaucoma and other serious ophthalmic conditions.

While specific financial terms of the agreement were not disclosed, Glaukos will fund the preclinical research of NCX 1728, with a focus on treating glaucoma through neuroprotection, as well as exploring its potential for retinal diseases. A Joint Steering Committee composed of members from both companies will oversee the collaborative research program.

In addition to the initial research investment, Glaukos holds an option to license NCX 1728 globally for further development in these ophthalmic conditions. This option can be exercised within specific periods, the first of which is set for 12 months from the agreement's signing. Should Glaukos choose to license the compound, pre-agreed economic terms for such a deal would go into effect, providing a framework for future financial and development commitments, according to Nicox. 

“Glaukos possesses expertise in the treatment of ophthalmic disorders and has unique drug delivery capabilities which could optimize NCX 1728 for uses including reduction of intraocular pressure, neuroprotection, and as a potential treatment for retinal diseases," Doug Hubatsch, Chief Scientific Officer of Nicox, said in a company news release. "Glaukos is therefore an ideal partner to accelerate the research and development of this unique compound and deliver on its therapeutic potential. We look forward to working with Glaukos to evaluate the use of this novel molecule in multiple different indications.”

NCX 1728, as a nitric oxide-donating PDE5 inhibitor, holds promise in the reduction of IOP. Additionally, its potential for neuroprotection could represent a breakthrough in managing and preventing damage to the optic nerve, Nicox stated. The molecule's application in retinal diseases could also open up new avenues for treating degenerative eye conditions.